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Abstract We demonstrated that adrenomedullin (AM) inhibited
interleukin-1L-induced tumor necrosis factor-K (TNF-K) secre-
tion and gene transcription in Swiss 3T3 fibroblasts maximally to
23% and 18% of control, while the other peptides elevating
intracellular cAMP levels elicited much weaker effects. AM
rapidly reduced the gene transcript level of TNF-K, inducing a
maximal effect within 1 h. The inhibitory effect of AM was
restored with an AM receptor antagonist as well as a cAMP-
dependent protein kinase inhibitor. These findings indicate that
AM is a potent and quick suppressor of TNF-K production in
Swiss 3T3 cells acting through the cAMP protein kinase A
pathway. As TNF-K is a major inflammatory cytokine and
stimulates AM production in fibroblasts, AM is deduced to be an
autocrine or paracrine factor suppressing inflammation through
the inhibition of TNF-K production.
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1. Introduction
Adrenomedullin (AM) is a potent vasorelaxant peptide ¢rst
isolated from extracts of human pheochromocytoma [1]. This
peptide of 52 residues structurally belongs to the calcitonin
gene-related peptide (CGRP) family [2]. In our systematic
survey for AM producing cells, vascular smooth muscle cells
(VSMCs), endothelial cells (ECs), monocytes, and macro-
phages were shown to actively produce and secrete AM
[3^6]. The production of AM in VSMCs and ECs is strongly
augmented by tumor necrosis factor (TNF), interleukin-1 (IL-
1), and lipopolysaccharide (LPS) [3,7,8]. We have recently
demonstrated that ¢broblasts actively synthesize and secrete
AM at a rate comparable to or higher than that of ECs and
VSMCs [9]. TNF-K, IL-1L, and LPS are also potent stimu-
lants of AM production in the ¢broblasts [9]. In the in vivo
study, markedly elevated levels of AM were observed in the
plasma of LPS-injected rats and patients with septic shock
[10,11]. These data suggest that AM secreted from ¢broblasts
signi¢cantly contributes to the elevation of plasma AM con-
centration in septic shock and in£ammation. On the other
hand, ¢broblasts express receptors for AM, and AM is a
powerful stimulator of cAMP production especially in Swiss
3T3 ¢broblasts [9]. In fact, AM stimulates proliferation as
well as IL-6 production in Swiss 3T3 cells through its receptor
and cAMP-dependent protein kinase (PKA) pathway [9,12].
Based on the data described above, AM is expected to par-
ticipate in the mediation of in£ammation and septic shock in
addition to vasodilation.
TNF-K is well known as a major factor inducing in£amma-
tion and immune responses and is secreted abundantly from
monocytes and macrophages, especially under the stimulation
with IL-1 and LPS [13,14]. Fibroblasts, in addition to macro-
phages and monocytes, have been recognized as one of the
possible sources of TNF-K in septic shock and in£ammation
[15^17]. To elucidate the functions of AM secreted from ¢-
broblasts and assess its contribution to the in£ammation, we
measured the e¡ects of AM on the basal and IL-1L-induced
TNF-K secretion from Swiss 3T3 ¢broblasts.
2. Materials and methods
2.1. Materials
The following materials were used: mouse recombinant IL-1L (In-
tergen), mouse recombinant TNF-K (Boehringer Mannheim), H-89
(N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide) and
H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine) (Seikagaku
Corp.), genistein (Calbiochem), PD98059 (2P-amino-3P-methoxy£a-
vone) (New England Biolabs). Peptides were obtained from Peptide
Institute, and all of them used were of human origin except for those
speci¢cally identi¢ed by the species name. All substances were dis-
solved according to the producer’s manuals and diluted with an in-
cubation medium, Dulbecco’s modi¢ed Eagle’s medium (DMEM)
containing 1% fetal calf serum (FCS) (Filtron).
2.2. Cell culture
3T3 Swiss albino (Swiss 3T3) cells and NCTC clone 929 (L929) cells
were purchased from American Type Culture Collection. Swiss 3T3
cells were maintained in DMEM containing 10% FCS at 37‡C in a
humidi¢ed atmosphere containing 5% CO2. L929 cells were main-
tained in minimum essential medium (MEM) containing 10% horse
serum at 37‡C in a humidi¢ed atmosphere containing 5% CO2.
2.3. Preparation of conditioned medium
Swiss 3T3 cells, grown to con£uence in a 6-well plate (Iwaki Glass),
were washed twice with DMEM and incubated with the incubation
media containing reagents to be tested at 37‡C for 0^48 h in a CO2
incubator. The culture media were collected and kept at 385‡C until
analysis. More than 95% of the cells were viable under these incuba-
tion conditions, estimated by the trypan blue exclusion assay.
2.4. Measurement of TNF-K
Biologically active TNF-K in the conditioned medium was meas-
ured by the cell cytotoxicity assay, using mouse ¢broblast L929 cells
[18]. L929 cells were cultured in a 24-well plate at a concentration of
5U104 cells/well and incubated for 24 h at 37‡C in a humidi¢ed
atmosphere containing 5% CO2. The cells were then incubated with
the conditioned media or mouse TNF-K as a standard in the medium
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 6 1 5 - 4
*Corresponding author. Fax: (81)-6-6872-7485.
E-mail: minamino@ri.ncvc.go.jp
Abbreviations: AM, adrenomedullin; TNF, tumor necrosis factor;
IL, interleukin; LPS, lipopolysaccharide; PKA, cAMP-dependent
protein kinase; EC, endothelial cell ; VSMC, vascular smooth muscle
cell ; CGRP, calcitonin gene-related peptide
FEBS 23045 2-12-99
FEBS 23045FEBS Letters 463 (1999) 110^114
containing 5-[125I]-Iodo-2P-deoxyuridine (125I-DU, 0.1 WCi/ml) (Amer-
sham) and 0.5 Wg/ml actinomycin D (Sigma). After a 24-h incubation,
the L929 cells were washed twice with ice-cold PBS, and the radio-
activity of 125I-DU incorporated into nuclei was extracted and
counted by the method reported previously [9]. A monoclonal anti-
body against mouse TNF-K (Genzyme) was used to determine
whether or not the cytotoxic activity observed was derived from
TNF-K.
2.5. Quanti¢cation of TNF-K gene transcript level by real time
quantitative PCR
Swiss 3T3 cells, grown to con£uence in a 6-well plate, were washed
twice with DMEM and incubated with the incubation media contain-
ing stimulants for 0^8 h. Total RNA was extracted and reverse-
transcribed into cDNA with SuperScript II (Life Technologies).
Mouse TNF-K cDNA and GAPDH cDNA were each ampli¢ed
with respective pairs of the following oligonucleotides: GTGATC-
GGTCCCCAAAGG (base 326^343, sense) and GGGTCTGGGCCA-
TAGAACTG (base 394^414, antisense) for TNF-K [6], ACATGTTC-
CAGTATGACTCCACTCAC (base 174^199, sense) and TCTCG-
CTCCTGGAAGATGGT (base 282^301, antisense) for GAPDH [6].
To measure mouse TNF-K and GAPDH gene transcript levels, real
time quantitative PCR (Prism 7700 Sequence Detector, Applied Bio-
systems) was performed as reported previously [6]. We used the fol-
lowing oligonucleotide probes labeled with the reporter and quencher
£uorescence: ATGAGAAGTTCCCAAATGGCCTCCCT (base 346^
369) for TNF-K, and AACGGCACAGTCAAGGCCGAGAAT (base
209^233) for GAPDH. TNF-K gene transcript levels were compared
after correcting them by a GAPDH gene transcript level as an internal
standard. Known amounts of cDNA fragments of mouse TNF-K
(base 326^414) and GAPDH (base 174^301) were used as standards.
The data were averages of four experiments.
2.6. Statistics
Values were expressed as mean þ S.E.M. Statistical analysis of the
results was performed with a one-way analysis of variance (ANOVA),
followed by a multiple comparison test (Dunnett’s test), and P6 0.05
was considered signi¢cant.
3. Results
3.1. E¡ect of AM on TNF-K secretion and gene transcription in
Swiss 3T3 cells
TNF-K concentration in the culture medium of non-stimu-
lated Swiss 3T3 cells was determined to be 4.1 þ 0.14 pg/ml
(basal) after a 24-h incubation. AM alone was of no e¡ect on
the basal TNF-K secretion level from Swiss 3T3 cells in a
range of 10310^1037 M (Fig. 1a). As TNF-K production in
macrophages, astrocytes, and ¢broblasts has been reported to
be stimulated with IL-1 [13,19,20], we examined whether AM
a¡ects TNF-K synthesis and secretion from Swiss 3T3 cells in
the presence of IL-1L. TNF-K concentration in the medium of
Swiss 3T3 cells after a 24-h stimulation with IL-1L (1 ng/ml)
was determined to be 14.9 pg/ml (control), which was 3.6-fold
higher than the basal level. AM dose-dependently inhibited
TNF-K secretion from IL-1L-stimulated Swiss 3T3 cells in a
physiological concentration range of 1039^1037 M, and TNF-
K concentration was decreased to 23% of the control after a
24-h incubation. The 50% inhibitory concentration (IC50) val-
ue for AM was 1U1039 M. The cytotoxic activity in the
conditioned media of Swiss 3T3 cells in the presence (control)
or absence (basal) of IL-1L was inhibited by 91% and 88%
with the neutralizing monoclonal antibody against mouse
TNF-K (25 Wg/ml). These ¢ndings indicate that the cytotoxic
activity in the conditioned medium of Swiss 3T3 cells was
almost completely derived from TNF-K secreted from Swiss
3T3 cells. We also examined the e¡ects of AM on the TNF-K
gene transcription in Swiss 3T3 cells using the real time quan-
titative PCR. AM dose-dependently decreased a TNF-K gene
transcript level in Swiss 3T3 cells stimulated with IL-1L (1 ng/
ml) to 18% of the control in a manner similar to the protein
level after a 1-h incubation (Fig. 1b). CGRP also inhibited
TNF-K secretion from IL-1L-stimulated Swiss 3T3 cells, with
the IC50 value (1U1038 M) being 10 times higher than AM.
Rat amylin weakly suppressed TNF-K secretion from IL-1L-
stimulated Swiss 3T3 cells at a concentration of 1037 M, while
1037 M of vasoactive intestinal peptide (VIP) and rat pituitary
adenylate cyclase-activating polypeptide (PACAP) did not al-
ter the TNF-K secretion under the stimulation with IL-1L.
3.2. E¡ects of AM receptor antagonists and protein kinase
inhibitors on TNF-K secretion from Swiss 3T3 cells
stimulated with AM and IL-1L
AM[22^52], an AM receptor antagonist, dose-dependently
restored an AM-suppressed TNF-K concentration in the me-
dium of Swiss 3T3 cells stimulated with IL-1L (1 ng/ml).
TNF-K concentration in the medium was completely returned
to the control level at 1035 M of AM[22^52], and this dose of
AM[22^52] alone did not alter the control TNF-K concentra-
tion at all. CGRP[8^37], a CGRP receptor antagonist, also
restored the AM-suppressed TNF-K concentration in the me-
dium of IL-1L-stimulated Swiss 3T3 cells in a manner and
potency similar to that of AM[22^52]. The e¡ects of AM
and CGRP receptor antagonists on AM-suppressed TNF-K
Fig. 1. E¡ects of AM, CGRP, amylin, VIP, and PACAP on secre-
tion and gene transcription of TNF-K in Swiss 3T3 cells. (a) Swiss
3T3 cells were stimulated for 24 h with the indicated concentrations
of the peptides and IL-1L (1 ng/ml). F, AM; b, AM+IL-1L ; R,
CGRP+IL-1L ; O, amylin+IL-1L ; a, PACAP+IL-1L ; E, VIP+IL-
1L. TNF-K concentrations were measured as described in Section 2.
Each point represents the mean þ S.E.M. of four separate wells. (b)
TNF-K gene transcript levels in Swiss 3T3 cells were measured by
real time quantitative PCR after a 1-h incubation with the indicated
concentrations of AM and IL-1L (1 ng/ml). TNF-K gene transcript
level was corrected using a GAPDH gene transcript level as an in-
ternal standard. Each point represents the mean þ S.E.M. of four
separate measurements. The basal TNF-K mRNA level was 0.44
fg/pg GAPDH mRNA. *P6 0.01 vs. TNF-K level stimulated with
IL-1L (F, excluded from comparison).
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production were quite similar to those reported for the inhib-
ition on AM-induced cAMP production in Swiss 3T3 cells [9].
AM has been reported to induce its e¡ects through the
cAMP-, Ca2-, or mitogen-activating protein kinase-mediated
pathway by a series of studies [8,9,21,22]. To identify the
signal transduction mechanism involved in the inhibitory ac-
tivity of AM, we administered four kinds of protein kinase
inhibitors to Swiss 3T3 cells in the presence of AM (1038 M)
and IL-1L (1 ng/ml) and measured TNF-K concentration in
the culture media. As shown in Fig. 2, PD98059 (mitogen-
activated protein kinase inhibitor), H-7 (protein kinase C in-
hibitor), and genistein (tyrosine kinase inhibitor) were not
e¡ective at all. H-89, an inhibitor for PKA, restored AM-sup-
pressed TNF-K concentration in the medium of IL-1L-stimu-
lated Swiss 3T3 cells to 77% of the control, while the same
dose of H-89 did not alter TNF-K secretion in the presence of
IL-1L.
3.3. Time-dependent e¡ects of AM and IL-1L on TNF-K
secretion and gene transcription in Swiss 3T3 cells
TNF-K concentrations in the culture media of Swiss 3T3
cells were measured up to 48 h under basal (no stimulation),
control (IL-1L, 1 ng/ml), and AM-suppressed (AM, 1038 M;
IL-1L, 1 ng/ml) conditions (Fig. 3a). Compared to the time-
course of the basal TNF-K level, IL-1L stimulated TNF-K
secretion from Swiss 3T3 cells over 48 h, where TNF-K con-
centration was 3.4-fold higher than the basal level. AM (1038
M) suppressed the TNF-K concentration to 34% and 24% of
the control after 1 h and 24 h, respectively. We also examined
from 0 to 8 h the e¡ect of AM (1038 M) on TNF-K gene
transcription in IL-1L-stimulated Swiss 3T3 cells (Fig. 3b).
TNF-K gene transcript level reached a maximum after a 1-h
stimulation with IL-1L, and then decreased to the basal level.
AM suppressed IL-1L-elevated TNF-K gene transcript level in
Swiss 3T3 cells from 0.5 to 4 h, particularly after a 1-h in-
cubation to 22% of the control.
4. Discussion
AM potently inhibited TNF-K secretion and gene transcrip-
tion in IL-1L-stimulated Swiss 3T3 cells to 23% and 18% of
the control, respectively. This inhibitory e¡ect is dose-depend-
ent within a physiological concentration range (Fig. 1). The
TNF-K concentration in the culture medium of IL-1L-stimu-
lated Swiss 3T3 cells was signi¢cantly decreased already after
a 1-h incubation with AM and was continually suppressed up
to 48 h. The TNF-K gene transcript level was elevated max-
imally 13-fold with IL-1L after a 1-h stimulation, and AM
strongly suppressed this quick increase of the TNF-K gene
transcript level (Fig. 3). These results suggest that AM is a
potent suppressor of TNF-K production in Swiss 3T3 cells.
H-89, a speci¢c inhibitor of PKA, restored AM-suppressed
TNF-K production to 77% of the control in the presence of
IL-1L (Fig. 2), while the inhibitors for the mitogen-activated
protein kinase, protein kinase C and tyrosine kinase were of
no e¡ect. IL-1L-induced TNF-K production in astrocytoma
and zona glomerulosa cells has also been shown to be regu-
lated by the cAMP-mediated pathway [23]. Taken together,
AM is found to inhibit IL-1L-induced TNF-K production
through the cAMP-PKA pathway by activating the recep-
tor-coupled adenylate cyclase.
Among the other examined peptides that are known to
elevate intracellular cAMP, CGRP and amylin weakly inhib-
Fig. 2. E¡ects of protein kinase inhibitors on AM-suppressed TNF-
K secretion from Swiss 3T3 cells. Swiss 3T3 cells were incubated for
24 h with the indicated combinations of AM (1038 M), H-89
(5U1036 M), PD98059 (5U1036 M), H-7 (5U1036 M), and geni-
stein (5U1036 M) under the stimulation of IL-1L (1 ng/ml). TNF-K
concentrations in the media were measured as described in Section
2. Control indicates TNF-K concentration in the medium of Swiss
3T3 cells stimulated with IL-1L. Each column represents the
mean þ S.E.M. of four separate wells. *P6 0.01 vs. TNF-K concen-
tration stimulated with AM and IL-1L.
Fig. 3. Time-course of TNF-K secretion and gene transcription in
Swiss 3T3 cells. (a) TNF-K concentrations in the medium were
measured after a 0^48-h incubation of Swiss 3T3 cells with IL-1L
(1 ng/ml) alone (F), AM (1038 M) and IL-1L (b), or without any
stimulation (R). Each point represents the mean þ S.E.M. of four
separate wells. TNF-K concentration stimulated with AM and IL-1L
is signi¢cantly lower than that stimulated with IL-1L after a 1-h in-
cubation (P6 0.01). (b) TNF-K gene transcript levels in Swiss 3T3
cells were measured after a 0^8-h incubation of the cells with IL-1L
(1 ng/ml) alone (F), or AM (1038 M) and IL-1L (b). TNF-K gene
transcript levels were plotted after correcting them based on the
GAPDH gene transcript levels. Each point represents the mean þ
S.E.M. of four separate measurements. TNF-K mRNA level stimu-
lated with AM and IL-1L is signi¢cantly lower than that stimulated
with IL-1L between 0.5-h and 2-h incubation (P6 0.01).
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ited IL-1L-induced TNF-K production, while VIP and PA-
CAP elicited no e¡ect (Fig. 1a). We have reported that
CGRP and amylin weakly inhibit 125I-labeled AM binding
to Swiss 3T3 cells and increase cAMP production at a con-
centration higher than 1038 or 1037 M [9]. Thus, the inhib-
itory e¡ects of CGRP and amylin on IL-1L-induced TNF-K
secretion were thought to be mediated by their binding to the
AM-speci¢c receptor and low elevation of the intracellular
cAMP in Swiss 3T3 cells. Although PACAP and VIP were
reported to inhibit LPS-induced TNF-K production in macro-
phages [24], these two peptides were able to elevate cAMP
production in Swiss 3T3 cells only to 1/30 that stimulated
with AM, resulting in no signi¢cant alteration of TNF-K se-
cretion. In fact, AM most potently stimulated cAMP produc-
tion in Swiss 3T3 cells among the peptides so far examined [9].
Based on these ¢ndings, AM is concluded to be the most
potent peptidergic suppressor of IL-1L-induced TNF-K pro-
duction in Swiss 3T3 cells.
McLatchie et al. have demonstrated that AM and CGRP
share a core receptor, calcitonin receptor-like receptor
(CRLR) [25]. The CRLR is speci¢c for AM when it is co-
expressed with receptor activity-modifying protein (RAMP)-2
or RAMP-3, while this receptor turns to be speci¢c for CGRP
when co-expressed with RAMP-1. AM, CGRP, AM[22^52]
and CGRP[8^37] have been reported to inhibit 125I-labeled
rat AM binding to the membrane preparation of HEK293T
cells expressing CRLR and RAMP-2 with the IC50 values of
7.5U10310, 1.3U1036, 1.5U1038 and 7.5U1038 M, respec-
tively [25]. As for Swiss 3T3 cells, we have reported that these
four peptides inhibit its binding to the cells with the IC50
values of 4.1U1039, 5.1U1037, 9.0U1037 and 6.0U1038 M
[9], and AM[22^52] and CGRP[8^37] elicited the comparable
inhibitory e¡ects in this study. Based on these data, it is rather
hard to deduce that the action of AM on Swiss 3T3 cells is
induced simply through the CRLR and RAMP-2, even
though we used the receptor system of di¡erent species. Bu«hl-
mann et al. have recently found that the speci¢city of the
CRLR is shifted when two RAMPs are expressed together
[26]. Our preliminary studies indicate that more than two
types of the RAMPs are usually expressed at the di¡erent
ratios in each cell line. Taken together, it is necessary to
quantitatively measure the expression levels of CRLR and
RAMPs to elucidate the signal transduction of AM and
CGRP through the cell membrane.
In addition to ¢broblasts, ECs and VSMCs, we have re-
ported that AM is secreted from monocytes, macrophages,
and related cell lines especially under in£ammatory condi-
tions. In the case of macrophage-derived RAW264.7 cells,
AM apparently suppressed LPS-induced TNF-K production
[6]. In this and preceding studies, we demonstrated that AM
was actively secreted from ¢broblasts and suppressed IL-1L-
induced TNF-K production. These results suggest that AM
can generally suppress TNF-K production. On the other
hand, we have reported that AM stimulates a basal as well
as TNF-K-, IL-1L-, or LPS-induced IL-6 production in Swiss
3T3 cells [12]. Although IL-6 is classi¢ed into the proin£am-
matory cytokine, it has been reported that IL-6 inhibits TNF-
K production in vitro and in vivo [27^29]. Thus, both AM and
IL-6 are deduced to alter TNF-K production in the same
direction. TNF-K is well known as a major in£ammatory
cytokine in in£ammatory responses, because the administra-
tion of monoclonal antibody against TNF-K or soluble TNF
receptor blocks various acute and chronic responses in animal
models of in£ammatory diseases [13]. Based on these data,
AM is deduced to function as an autocrine or paracrine factor
suppressing the propagation of in£ammation through the in-
hibition of TNF-K production, and the in£ammatory cyto-
kines may utilize AM as a feedback regulator of their produc-
tion. Glucocorticoid is a potent anti-in£ammatory drug, but it
stimulates AM production in many types of cells [8,9,30]. The
suppressive e¡ect of AM on the cytokine-induced TNF-K
production might be involved in a part of the anti-in£amma-
tory action of the glucocorticoid.
In conclusion, we demonstrated that AM potently inhibited
IL-1L-induced TNF-K gene transcription and secretion from
Swiss 3T3 ¢broblasts through the cAMP-PKA pathway. As
¢broblasts actively synthesize and secrete AM, these ¢ndings
suggest that AM is an autocrine or paracrine anti-in£amma-
tory factor in the mesenchymal tissue.
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